Watch why Voclosporin should be propelling AUP to over $100! Very, very few biotech companies succeed in getting to market.

Dr. Robert Foster incorporated Isotechnika Pharma in 1993, where he served as the company’s Chairman and CEO until 2014. There, Dr. Foster discovered voclosporin, which 28 years later, has been approved by the U.S. Food and Drug Administration (FDA) as LUPKYNIS to treat patients with active lupus nephritis (LN).

LUPKYNIS, commercialized by Aurinia Pharmaceuticals Inc., is the first FDA-approved oral therapy for LN, which causes irreversible kidney damage and significantly increases the risk of kidney failure, cardiac events, and death. It is one of the most serious and common complications of the autoimmune disease systemic lupus erythematosus (SLE).

“The whole purpose of creating a biotechnology company and developing drugs is to bring patients that are suffering into remission, and do it as quickly as possible with minimal side effects,” says Dr. Foster. “That's what voclosporin—now LUPKYNIS—is currently doing. It’s the first oral medication to be approved by the FDA for the treatment of lupus nephritis. It is safe, well tolerated, and efficacious.”